Ovarian Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition:   Ovarian Cancer Recurrent Interventions:   Drug: IN10018;   Drug: Placebo of IN10018;   Drug: Pegylated Liposomal Doxorubicin Sponsor:   InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Endometrial Cancer Intervention:   Drug: HS-20089 Sponsor:   Hansoh BioMedical R&D  Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition:   Ovarian Cancer Recurrent Interventions:   Drug: IN10018;   Drug: Placebo of IN10018;   Drug: Pegylated Liposomal Doxorubicin Sponsor:   InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Endometrial Cancer Intervention:   Drug: HS-20089 Sponsor:   Hansoh BioMedical R&D  Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition:   Ovarian Cancer Recurrent Interventions:   Drug: IN10018;   Drug: Placebo of IN10018;   Drug: Pegylated Liposomal Doxorubicin Sponsor:   InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Endometrial Cancer Intervention:   Drug: HS-20089 Sponsor:   Hansoh BioMedical R&D  Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition:   Ovarian Cancer Recurrent Interventions:   Drug: IN10018;   Drug: Placebo of IN10018;   Drug: Pegylated Liposomal Doxorubicin Sponsor:   InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials